Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 18/20 | 0.40 |
| ▸ | INSR | P06213 | 2/20 | 0.39 |
| ▸ | LCK | P06239 | 2/20 | 0.39 |
| ▸ | LTK | P29376 | 2/20 | 0.39 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.39 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.39 |
| ▸ | MERTK | Q12866 | 2/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18779209 | 0.88 | ALK (0.41) | ALKINSRLCKLTKAXL | |
| SCHEMBL18779180 | 0.87 | ALK (0.41) | ALKINSRLCKLTKAXL | |
| SCHEMBL18791477 | 0.85 | EGFR (0.43) | ALKINSRLCKLTKAXL | |
| SCHEMBL18791979 | 0.85 | EGFR (0.42) | ALKINSRLCKLTKAXL | |
| SCHEMBL17582978 | 0.85 | ALK (0.44) | ALKINSRLCKLTKAXL | |
| SCHEMBL17582926 | 0.85 | ALK (0.44) | ALKINSRLCKLTKAXL | |
| SCHEMBL24846711 | 0.84 | CYP19A1 (0.33) | ALKINSRLCKLTKAXL | |
| SCHEMBL18779186 | 0.84 | ALK (0.46) | ALKINSRLCKLTKAXL | |
| SCHEMBL21375822 | 0.83 | ALK (0.42) | ALKINSRLCKLTKAXL | |
| SCHEMBL18779192 | 0.82 | ALK (0.42) | ALKINSRLCKLTKAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-08-15 | — | — | US | disclosed |
| US-20230000831-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | ALK 2337/4885INSR 3988/4885LCK 485/4885 |
| US-20230000831-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | ALK 2337/4885INSR 3988/4885LCK 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.